Telix Pharmaceuticals has announced a transformational merger with ITM Isotope Technologies Munich SE, a strategic combination that creates a vertically integrated radiopharmaceutical powerhouse. The deal values ITM at US$1.65 billion on a cash-free, debt-free basis, with ITM shareholders receiving approximately US$1.25 billion in Telix shares priced at US$11.841 per share, plus additional contingent payments of up to US$700 million based on future regulatory approvals and commercial milestones.
The strategic logic is compelling for Telix. ITM is the world’s leading supplier of therapeutic radioisotopes, with commercial-scale production capabilities spanning lutetium-177, actinium-225, and terbium-161. The Munich-based company is the only global producer of commercially-scaled, high-purity lutetium-177, an isotope critical to radiopharmaceutical development. With a compound annual growth rate of 40 percent from 2021 to 2025 and audited revenue of US$273 million in 2025, ITM brings both scale and proven cash generation to the combined entity.
Beyond supply assurance, ITM contributes a valuable clinical-stage asset. ITM-11, a novel therapeutic candidate for gastroenteropancreatic neuroendocrine tumors, has successfully completed Phase 3 development. This represents a near-term commercial opportunity in a validated market for targeted radionuclide therapy, potentially accelerating Telix’s path to revenue in this therapeutic category. The asset could reach commercialization without the typical early-stage development risk, providing material upside to the contingent consideration structure.
The transaction consolidates the radiopharmaceutical value chain in a way few competitors can replicate. Telix gains secure isotope supply for its extensive therapeutic pipeline while eliminating dependence on external suppliers for its most critical manufacturing input. For ITM, the combination offers access to Telix’s market-leading precision medicine platform and global distribution network spanning more than 65 countries, creating cross-selling opportunities and deepening customer relationships.
Investors should note the significant financial commitment. The US$1.65 billion upfront consideration reflects a substantial capital deployment for Telix, though payable in stock rather than cash. The contingent payments introduce execution risk but align shareholder interests with ITM-11’s regulatory and commercial success. Given Telix’s current development stage, the stock consideration matters more than the headline valuation. With shares priced at US$11.841, the exchange ratio assumes significant price appreciation from announcement levels or reflects confidence in Telix’s near-term catalysts.
The merger requires Telix shareholder approval and remains subject to customary closing conditions. Key milestones to monitor include the shareholder vote, regulatory clearances, and the investor reception. An investor conference call is scheduled for 9:30 a.m. AEST on Monday, September 21, 2026. This announcement has been flagged as price sensitive and is classified as material by the ASX.
View the full ASX announcement (PDF)
About TELIX Pharmaceuticals Limited (ASX: TLX)
TELIX Pharmaceuticals Limited is a commercial-stage biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals for oncology and other serious diseases. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions, focusing on targeted radiation therapies for various cancer indications. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
